Half-life extended factor VIII for the treatment of hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S176-S179

  Tiede, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Blood coagulation factors; Hemophilia A; Hemostasis; Polyethylene glycol; Recombinant proteins

Indexed keywords

MACROGOL; N8 GP; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; HEMOSTATIC AGENT; NEW DRUG; RECOMBINANT PROTEIN;

BINDING AFFINITY; CHEMOPROPHYLAXIS; CHEST TIGHTNESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HEMOPHILIA A; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; URTICARIA; ANIMAL; BLOOD; DRUG DEVELOPMENT; DRUG EFFECTS; HALF LIFE TIME; HEMORRHAGE; HEMOSTASIS; TREATMENT OUTCOME;

ANIMALS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HEMOSTATICS; HUMANS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84931416208     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12929     Document Type: Review

References (18)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
3. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
4. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7.
5. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
6. Stennicke HR, Kjalke M, Karpf DM, Balling KW, Johansen PB, Elm T, Ovlisen K, Moller F, Holmberg HL, Gudme CN, Persson E, Hilden I, Pelzer H, Rahbek-Nielsen H, Jespersgaard C, Bogsnes A, Pedersen AA, Kristensen AK, Peschke B, Kappers W, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108-16.
7. Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-8.
8. Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
9. Gu JM, Ramsey P, Evans V, Tang L, Apeler H, Leong L, Murphy JE, Laux V, Myles T. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014; 20: 593-600.
10. Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12: 488-96.
11. Reding MT, Powell J, Santagostino E, Ng HJ, Lederman M, Wang M, Walsch R, Sax M, Michaels LA. Safety and efficacy of prophylaxis and on-demand treatment with BAY 94-9027: results of a phase 2/3, multicenter, partially randomized, open-label trial (PROTECT VIII). Haemophilia 2014; 20 (Suppl. 3): 20.
12. Turecek PL, Bossard MJ, Graninger M, Gritsch H, Hollriegl W, Kaliwoda M, Matthiessen P, Mitterer A, Muchitsch EM, Purtscher M, Rottensteiner H, Schiviz A, Schrenk G, Siekmann J, Varadi K, Riley T, Ehrlich HJ, Schwarz HP, Scheiflinger F. BAX, 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32 (Suppl. 1): S29-38.
13. Valentino LA, Cong L, Enockson C, Song X, Scheiflinger F, Muchitsch EM, Turecek PL, Hakobyan N. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule. Haemophilia 2015; 21: 58-63.
14. Bevan DH, Conlan M, Mant T, Lissitchkov T, Kazmi R, Chowdary P, Langer F, Shima M, Fukutake K, Singer J, Grigorian A, Ewenstein B, Wong WY. A phase 1 study of safety and pharmacokinetics (PK) of BAX 855, a longer acting PEGylated full-length recombinant factor VIII (PEG-rFVIII), in patients with severe haemophilia A. EAHAD 2013 poster presentation.
15. Schulte S. Pioneering designs for recombinant coagulation factors. Thromb Res 2011; 128 (Suppl. 1): S9-12.
16. Zollner SB, Raquet E, Muller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res 2013; 132: 280-7.
17. Zhang Y, Limsakun T, Bensen-Kennedy DM, Veldman A, Yao Z. Population pharmacokinetic modeling and simulation of recombinant single-chain factor VIII (rVIII-SingleChain) in patients with hemophilia A. Blood 2014; ASH Annual Meeting Abstract No. 2814.
18. Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.